European Medicines Agency accepts Marketing Authorization Application for conditional approval of masitinib in the treatment of pancreatic cancer. PARIS--(BUSINESS WIRE)-- Regulatory News: AB Science ...

Changing the administration schedule for Gemzar (gemcitabine) plus Abraxane (nab-paclitaxel) from weekly to every other week significantly reduced side effects without impacting efficacy as a ...

CHICAGO, June 2, 2007 -- GEMZAR® (gemcitabine HCl for injection), approved in combination with paclitaxel (Taxol®) in the first-line, post-surgical treatment of metastatic breast cancer, was the ...

Celgene Corporation’s CELG shares gained 3.2% after the company announced results from multiple analyses from the phase III study, MPACT on oncology drug Abraxane (paclitaxel protein-bound particles ...

Fresh off one blockbuster patent defense, Eli Lilly and Co. mounted another last month when it filed suit to protect its billiondollar cancer drug Gemzar. The Indianapolis drugmaker sued Teva ...

JERUSALEM--(BUSINESS WIRE)-- Teva Pharmaceutical Industries Ltd. (Nasdaq: TEVA) and APP Pharmaceuticals, Inc. announced today the commercial launch of Gemcitabine HCI for Injection in 200 mg and 1 g ...

NEW YORK (Reuters) - A decision by a U.S. appeals court could pave the way for cheaper generic forms of Eli Lilly and Co's Gemzar cancer drug to be launched in the United States beginning in ...

A US Food and Drug Administration advisory committee declined to back approval of Eli Lilly’s Gemzar as a treatment for ovarian cancer yesterday, saying the data submitted by the company were not ...

Nov. 10, 2005 -- The U.S. Food and Drug Administration (FDA) has approved clobetasol propionate 0.05% spray for the treatment of moderate to severe plaque psoriasis affecting up to 20% of body surface ...

Indianapolis-based Eli Lilly and Co. has failed to win an appeals court rehearing over its loss of patent protection for the cancer drug Gemzar. The U.S. Court of Appeals for the Federal Circuit today ...

(NYSE Euronext - FR0010557264 - AB), a pharmaceutical company specializing in the research, development and commercialization of protein kinase inhibitors, announced today the results from a phase 3 ...